Secondary Malignant Neoplasm — Trials

Secondary Malignant Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

14,671 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 4,275
Recruiting: 2,321
Ph III recruiting: 272
Growth YoY: +12.3%
Industry share: 22%
Top sponsor: National Cancer Institute (NCI)
Termination share: 35.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,961)

clinicaltrialsPublishedShowing 401–450 of 6,412 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03457948	Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases	completed	Phase 2	32	Nicholas Fidelman, MDOTHER	1	Aug 28, 2026	clinicaltrials
NCT03595124	A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)	active not recruiting	Phase 2	15	National Cancer Institute (NCI)NIH	2	Aug 28, 2026	clinicaltrials